{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:19:10Z","timestamp":1788135550143,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development"},{"DOI":"10.13039\/501100006012","name":"Christian Doppler Research Association.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54627-5","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T08:46:35Z","timestamp":1781426795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of liver disease regression in murine models of liver fibrosis and portal hypertension"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-1148","authenticated-orcid":false,"given":"Philipp","family":"K\u00f6nigshofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8234-5875","authenticated-orcid":false,"given":"Ksenia","family":"Brusilovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3403-3372","authenticated-orcid":false,"given":"Benedikt S.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-4910","authenticated-orcid":false,"given":"Oleksandr","family":"Petrenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-9146","authenticated-orcid":false,"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bareiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Zinober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Regnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-7881","authenticated-orcid":false,"given":"Vlad","family":"Taru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-4851","authenticated-orcid":false,"given":"Thomas","family":"Sorz-Nechay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1616-0161","authenticated-orcid":false,"given":"Katharina","family":"Bonitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-006X","authenticated-orcid":false,"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Stojakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4524-8578","authenticated-orcid":false,"given":"Stefan G.","family":"Kauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-8076","authenticated-orcid":false,"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"54627_CR1","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.cgh.2022.11.033","volume":"21","author":"BS Hofer","year":"2023","unstructured":"Hofer, B. S. et al. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. Clin. Gastroenterol. Hepatol. 21, 2308\u20132317 (2023). e7.","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"54627_CR2","doi-asserted-by":"crossref","unstructured":"Semmler, G. et al. Influence of genetic variants on disease regression and outcomes in HCV-related advanced chronic liver disease after SVR. J. Pers. Med. 11. (2021).","DOI":"10.3390\/jpm11040281"},{"key":"54627_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18, 151\u2013166 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"54627_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola, M. & Pinzani, M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol. Aspects Med. 65, 37\u201355 (2019).","journal-title":"Mol. Aspects Med."},{"key":"54627_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10238-022-00799-z","volume":"23","author":"AB Chowdhury","year":"2023","unstructured":"Chowdhury, A. B. & Mehta, K. J. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin. Exp. Med. 23, 273\u2013285 (2023).","journal-title":"Clin. Exp. Med."},{"key":"54627_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/hep.22745","volume":"49","author":"V Calvaruso","year":"2009","unstructured":"Calvaruso, V. et al. Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49, 1236\u20131244 (2009).","journal-title":"Hepatology"},{"key":"54627_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbadis.2017.07.026","volume":"1864","author":"M Pinzani","year":"2018","unstructured":"Pinzani, M. & Luong, T. V. Pathogenesis of biliary fibrosis. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1279\u20131283 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"54627_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/hep.32220","volume":"75","author":"P K\u00f6nigshofer","year":"2022","unstructured":"K\u00f6nigshofer, P. et al. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology 75, 610\u2013622 (2022).","journal-title":"Hepatology"},{"key":"54627_CR9","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Y Iwakiri","year":"2021","unstructured":"Iwakiri, Y. & Trebicka, J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep. 3, 100316 (2021).","journal-title":"JHEP Rep."},{"key":"54627_CR10","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.jhepr.2022.100513","volume":"4","author":"L Balcar","year":"2022","unstructured":"Balcar, L. et al. Risk of further decompensation\/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 4, 100513 (2022).","journal-title":"JHEP Rep."},{"key":"54627_CR11","doi-asserted-by":"crossref","unstructured":"Reiberger, T. et al. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J. Vis. Exp. (2020).","DOI":"10.3791\/58819"},{"key":"54627_CR12","doi-asserted-by":"crossref","unstructured":"K\u00f6nigshofer, P. et al. Invasive hemodynamic characterization of the portal-hypertensive syndrome in cirrhotic rats. JoVE :e57261. (2018).","DOI":"10.3791\/57261"},{"key":"54627_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","volume":"35","author":"YO Kweon","year":"2001","unstructured":"Kweon, Y. O. et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J. Hepatol. 35, 749\u2013755 (2001).","journal-title":"J. Hepatol."},{"key":"54627_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1053\/gast.2002.33367","volume":"122","author":"MJ Arthur","year":"2002","unstructured":"Arthur, M. J. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 122, 1525\u20131528 (2002).","journal-title":"Gastroenterology"},{"key":"54627_CR15","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/hep.20251","volume":"39","author":"JB Dixon","year":"2004","unstructured":"Dixon, J. B. et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39, 1647\u20131654 (2004).","journal-title":"Hepatology"},{"key":"54627_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis, R. et al. Baveno VII - Renewing consensus in portal hypertension. J. Hepatol. 76, 959\u2013974 (2022).","journal-title":"J. Hepatol."},{"key":"54627_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","volume":"55","author":"T Reiberger","year":"2023","unstructured":"Reiberger, T. & Hofer, B. S. The Baveno VII concept of cirrhosis recompensation. Dig. Liver Dis. 55, 431\u2013441 (2023).","journal-title":"Dig. Liver Dis."},{"key":"54627_CR18","doi-asserted-by":"publisher","first-page":"e0216301","DOI":"10.1371\/journal.pone.0216301","volume":"14","author":"SA El Awdan","year":"2019","unstructured":"El Awdan, S. A. et al. Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers. PLoS One. 14, e0216301 (2019).","journal-title":"PLoS One"},{"key":"54627_CR19","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1053\/j.gastro.2004.03.009","volume":"126","author":"R Issa","year":"2004","unstructured":"Issa, R. et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126, 1795\u20131808 (2004).","journal-title":"Gastroenterology"},{"key":"54627_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fphar.2018.00410","volume":"9","author":"ZM Ding","year":"2018","unstructured":"Ding, Z. M. et al. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Front. Pharmacol. 9, 410 (2018).","journal-title":"Front. Pharmacol."},{"key":"54627_CR21","doi-asserted-by":"publisher","first-page":"109301","DOI":"10.1016\/j.isci.2024.109301","volume":"27","author":"O Petrenko","year":"2024","unstructured":"Petrenko, O. et al. Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension. iScience 27, 109301 (2024).","journal-title":"iScience"},{"key":"54627_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bbadis.2018.07.018","volume":"1865","author":"P K\u00f6nigshofer","year":"2019","unstructured":"K\u00f6nigshofer, P. et al. Animal models of portal hypertension. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1019\u20131030 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"54627_CR23","doi-asserted-by":"publisher","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","volume":"8","author":"P Schwabl","year":"2018","unstructured":"Schwabl, P. et al. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci. Rep. 8, 9372 (2018).","journal-title":"Sci. Rep."},{"key":"54627_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","volume":"66","author":"P Schwabl","year":"2017","unstructured":"Schwabl, P. et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J. Hepatol. 66, 724\u2013733 (2017).","journal-title":"J. Hepatol."},{"key":"54627_CR25","doi-asserted-by":"publisher","first-page":"11808","DOI":"10.3389\/jpps.2023.11808","volume":"26","author":"OS Mohammed","year":"2023","unstructured":"Mohammed, O. S. et al. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. J. Pharm. Pharm. Sci. 26, 11808 (2023).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"54627_CR26","unstructured":"Russell, W. M. S. & Burch, R. L. The Principles of Humane Experimental Technique, (1959)."},{"key":"54627_CR27","first-page":"88","volume":"49","author":"Erratum to","year":"2014","unstructured":"Erratum to FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Lab. Anim. 49, 88\u201388 (2014).","journal-title":"Lab. Anim."},{"key":"54627_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0163-7258(89)90050-8","volume":"43","author":"RO Recknagel","year":"1989","unstructured":"Recknagel, R. O. et al. Mechanisms of carbon tetrachloride toxicity. Pharmacol. Ther. 43, 139\u2013154 (1989).","journal-title":"Pharmacol. Ther."},{"key":"54627_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.109.002014","volume":"62","author":"CD Klaassen","year":"2010","unstructured":"Klaassen, C. D. & Aleksunes, L. M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62, 1\u201396 (2010).","journal-title":"Pharmacol. Rev."},{"key":"54627_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal, A. J. et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75, 1235\u20131246 (2022).","journal-title":"Hepatology"},{"key":"54627_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller, R. & Brenner, D. A. Liver fibrosis. J. Clin. Invest. 115, 209\u2013218 (2005).","journal-title":"J. Clin. Invest."},{"key":"54627_CR32","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838\u2013851 (2008).","journal-title":"Lancet"},{"key":"54627_CR33","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s12072-023-10636-4","volume":"18","author":"B Simbrunner","year":"2024","unstructured":"Simbrunner, B. et al. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence. Hepatol. Int. 18, 929\u2013942 (2024).","journal-title":"Hepatol. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54627-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:10:22Z","timestamp":1788135022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54627-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54627"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54627-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PK and KBr were both co-supported by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development, Boehringer Ingelheim and the Christian Doppler Research Association. BS received travel support from AbbVie and Gilead. BSH received travel support from Ipsen. OP, KB, KZ, KR, VT, TSN, KBo, HS and TS declare no conflicts of interest. SGK & LP are employed by Boehringer Ingelheim Pharma GmbH & Co.KG. MT received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Jannsen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, MSD and Madrigal, as well as travel support from AbbVie, Falk, Gilead, Jannsen and Intercept. PS received consulting fees from PharmaIN. TR received grant support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD, MYR Pharmaceuticals, Philips Healthcare, Pliant and Siemens; speaking honoraria from AbbVie, Gilead Sciences, Gore, Intercept Pharmaceuticals, MSD and Roche; consulting or advisory board fees from AbbVie, Bayer, Boehringer Ingelheim, Gilead Sciences, Intercept Pharmaceuticals, MSD and Siemens; and travel support from AbbVie, Boehringer Ingelheim, Gilead Sciences and Roche.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27183"}}